Dr. Walker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
275 Collier Rd NW
Atlanta, GA 30309Phone+1 404-350-0009
Education & Training
- University of RochesterFellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2008
- Virginia Commonwealth University Health SystemResidency, Internal Medicine/Pediatrics, 2001 - 2005
- West Virginia University School of MedicineClass of 2001
Certifications & Licensure
- OH State Medical License 2018 - Present
- GA State Medical License 2011 - 2025
- WV State Medical License 2008 - 2011
- NY State Medical License 2006 - 2008
- VA State Medical License 2001 - 2005
- American Board of Pediatrics Pediatrics
Publications & Presentations
PubMed
- 176 citationsIvacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyMargaret Rosenfeld, Claire E. Wainwright, Mark Higgins, Linda T Wang, Charlotte M. McKee
The Lancet. Respiratory Medicine. 2018-07-01 - 268 citationsEfficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.Kris De Boeck, Anne Munck, Seth Walker, Albert Faro, Peter Hiatt
Journal of Cystic Fibrosis. 2014-12-01 - 40 citationsA phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.Seth Walker, Patrick A. Flume, John McNamara, Melinda Solomon, Mark A. Chilvers
Journal of Cystic Fibrosis. 2019-09-01
Journal Articles
- Tidal breathing responses to albuterol and normal saline in infants with viral bronchiolitis(1) Scarlett EE, Walker S, Rovitelli A, and Ren CL, Pediatric Allergy, Immunology, and Pulmonology, 12/1/2012
- Refusal of Venous Thromboembolism Prophylaxis and Incidence of Thrombosis in Patients with Cystic FibrosisTaryn S. Murray, PharmD, BCPS; Nicole L. Metzger, PharmD, BCPS; Melissa M. Chesson, PharmD, BCPS; Seth D. Walker, MD, PULMONARY RESEARCH AND RESPIRATORY MEDICINE – OPEN JOURNAL, 12/28/2017
- When will the Tobacco Control Act be considered a failure?Walker SD, Austin J Pulm Respir Med, 2014
Authored Content
- Cystic Fibrosis: Disease Manifestations and Current Therapies1/3/2017
Press Mentions
- An Open-Label Extension Study of Ivacaftor in Children with CF and a CFTR Gating Mutation Initiating Treatment at Age 2-5 Years (KLIMB)November 1st, 2019
- FDA Approves Symdeko for Treatment of CF Children, Ages 6 to 11, with Certain CFTR MutationsJune 25th, 2019
- Symdeko Approved to Treat Younger Cystic Fibrosis PatientsJune 24th, 2019
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: